To understand what sets izokibep apart from other IL-17 inhibitors and its potential for treating PsA, we spoke with one of the study's investigators, Prof. Peter Taylor. Prof. Taylor discusses the study's findings, focusing on its efficacy and tolerability, and explores what these results could mean for clinical practice. With several IL-17 inhibitors already approved or in development for PsA, we also examine how izokibep could fit into the current treatment paradigm. Additionally, we discuss the importance of ongoing research to fully determine izokibep's benefit/risk ratio and optimal dosage